RxSight Earnings Call Transcripts
Fiscal Year 2026
-
Premium ophthalmic solutions are gaining traction, with strong surgeon endorsement and a shift toward deeper utilization within existing accounts. International expansion is a major growth focus, supported by regulatory progress and significant planned investments. LAL maintains strong pricing and margin stability.
-
Achieved strong growth in procedures and sales, with a focus on premium adjustable IOLs that enhance patient outcomes and practice revenue. Organizational and commercial pivots are driving higher utilization, while international expansion and ongoing technical improvements position the business for further growth.
Fiscal Year 2025
-
Q4 2025 sales declined year-over-year due to lower LDD sales, but LAL revenue mix hit a record high and gross margins improved. 2026 guidance anticipates a modest revenue decline, with growth expected to rebound in the second half as commercial initiatives gain traction.
-
Management discussed recent market contraction, increased competition, and a strategic pivot to drive utilization and same-store sales. Financial guidance for 2025 was raised, with sequential growth expected in 2026. International expansion and operational realignment are key growth drivers.
-
Q3 revenue declined year-over-year but gross margin improved sharply due to a higher LAL mix. Guidance was narrowed with a focus on LAL volume growth and measured LDD placements, while international expansion and new clinical programs support long-term growth.
-
U.S. cataract surgery volumes declined early in the year, but premium IOL demand remained stable, with toric lenses favored for quality. Operational changes were made to improve new customer adoption, and international expansion is underway. The company continues to drive premium market growth, supported by strong clinical outcomes and favorable trends.
-
Guidance was reduced due to market and internal challenges, with a focus on driving same-store sales and customer adoption through organizational changes. International expansion is underway but will contribute modestly until 2027, while new product enhancements are expected to support future growth.
-
Q2 2025 revenue declined 4% year-over-year to $33.6 million, with LAL sales up but LDD sales down sharply. Full-year guidance was reiterated, projecting $120–$130 million in revenue and 72%–74% gross margin, as softness in LAL adoption and fewer new LDD sales are expected.
-
Revenue guidance for 2025 was sharply reduced due to lower LDD sales and slower LAL adoption, with management pivoting to a more supportive, data-driven commercial strategy. International expansion and peer-to-peer programs are key focus areas, while guidance remains conservative amid market and competitive headwinds.
-
LAL volumes improved as macro conditions stabilized, with premium IOL market growth driven mainly by LAL. Competitive headwinds are expected to ease in the second half of 2025, and growth initiatives focus on increasing utilization and market share.
-
Q1 revenue grew but missed expectations due to macroeconomic shocks, impacting premium product sales and leading to patient trade downs. LDD sales remained strong, with growth expected to accelerate in the second half of 2025 as economic conditions improve. International expansion is underway, with modest near-term contributions.
-
Q1 2025 revenue grew 28% year-over-year but declined sequentially, with macroeconomic and competitive pressures leading to a top-line miss. Gross margin improved to 74.8%, and full-year guidance was reiterated, with recovery expected in the second half.
-
Tariff exposure is limited due to U.S. manufacturing, with international launches proceeding cautiously. Market softness and competitive launches impacted Q1, leading to revised guidance and a more back-end loaded year. Long-term growth is expected from expanded access, international markets, and ongoing product innovation.
-
Q1 2025 revenue grew 28% year-over-year but declined sequentially, prompting a reduction in full-year guidance due to a softer premium IOL market, macroeconomic headwinds, and competitive disruptions. Gross margin guidance remains strong, and the company is investing in customer engagement and product innovation.
-
LAL technology is driving a paradigm shift in premium cataract surgery, with strong clinical outcomes, rapid revenue growth, and expanding adoption in North America. 2024 saw record revenue and implantations, with international expansion and continued innovation planned for 2025.
Fiscal Year 2024
-
Q4 2024 revenue rose 41% year-over-year to $40.2M, with record LAL procedure growth and gross margin expansion to 71.6%. 2025 guidance projects 32–41% revenue growth, continued margin improvement, and increased investment in sales, marketing, and R&D.
-
Q3 2024 saw 59% revenue growth year-over-year, driven by strong LAL and LDD sales, improved gross margin, and robust market adoption despite seasonal and weather-related headwinds. Full-year guidance was raised, with continued innovation and global expansion expected to sustain momentum.
-
Light Adjustable Lenses are gaining traction in the US premium IOL market, with strong revenue growth, ongoing product innovation, and a focus on expanding both domestically and internationally. The company is investing in R&D and education to drive adoption and sees a long runway for growth in the premium cataract segment.
-
Cataract surgery volumes are rising, with premium IOLs steadily gaining share and driving practice profitability. Adoption of Light Adjustable Lens technology is expanding, supported by ongoing product innovation, increased marketing, and plans for international growth.
-
Q2 2024 revenue rose 68% year-over-year to $34.9M, with strong LAL and LDD sales driving record results. Gross margin improved to 69.5%, and 2024 revenue guidance was raised to $139M–$140M, reflecting continued growth and product innovation.
-
The company is expanding its share in the premium IOL market with unique adjustable lens technology, strong adoption trends, and robust financial performance. Recent capital raised will support further U.S. education, R&D, and international expansion.